This thesis examines a small but unfashionable area of Scotland, invisible to tourist guidebooks, heavily urbanised, and whose towns have won environmental ‘Carbuncle awards’ from the Scottish media. Yet it is deep in Gaelic and Scots place-names which reveal a landscape that past inhabitants perceived to be a green and relatively pleasant land, if perhaps not flowing with milk and honey. Part Three belies its numeration, in that it is the core of the study, examining in detail the place-names of eight (modern) parishes, listing old forms and attempting a sound etymology for each. Part One, based on the data gathered for Part Three, attempts to seek patterns among these names, both between and within the languages concerned. Inter alia, it seeks to explore the degree to which the choice of elements for a particular name, from any language’s toponymicon, is conditioned by cultural, political and social influences ranging from feudal and parochial authorities, through the influence of Scots-speaking merchants, to onomastic local farming customs. The lessons derived from Part One were then used to shed light on some etymologies in Part Three: and hopefully will be of value to researchers in other areas of the country.

This thesis examines representations of ANGER in Old English by analysing occurrences of eight word families (YRRE, GRAM, BELGAN, WRĀÞ, HĀTHEORT, TORN, WĒAMŌD and WŌD) in prose and poetry. Through inspection of 1800 tokens across c. 400 texts, it determines the understanding of how ANGER vocabulary operates in the Old English lexicon and within the broader socio-cultural context of the period. It also helps refine the interpretations of wide-ranging issues such as authorial preference, translation practices, genre, and interpretation of literary texts. The thesis contributes to diachronic lexical semantics and the history of emotions by developing a replicable methodology that triangulates data from different sources. Chapter 1 introduces the field of study and shows the approaches to emotions as either universal or culturally-determined. It discusses previous analyses of ANGER in Old English and proposes a cross-linguistic, semasiological approach, which minimises ethnocentric bias. Categorisations and conceptualisations are not identical between languages, and Old English divides the emotional spectrum differently from Present-Day English. Chapter 2 presents the methodology, which draws on approaches from historical semantics and corpus linguistics, integrating methods from cognitive linguistics, anthropology and textual studies. Chapters 3 to 10 investigate each of the eight word families, analysing all occurrences in relation to grammatical category, collocations, range of meanings, and referents. Cognates in Germanic and other Indo-European languages, and Middle English and Early Modern English reflexes are examined to trace diachronic development. The thesis determines recurrent patterns of usage, distribution between text types, and socio-cultural significance. Specific passages from Old English from a range of genres are analysed and discussed. Each family is found to have a distinct profile of usage and distribution. Chapter 11 examines ANGER in the Old English translation of Gregory’s Regula pastoralis. This text exhibits usage not found in later prose or in poetry. The Cura pastoralis also presents a different framework for understanding and conceptualising ANGER to the one found in Latin. Finally, Chapter 12 synthesises my findings and considers them comparatively. These word families differ in usage, conceptual links, referents, and even authorial preferences. Most common portrayals of ANGER in Old English involve one of the three themes: ANGER AS VICE, WRATH OF GOD and ANGER AS HOSTILITY. The thesis demonstrates that a detailed analysis of lexical usage is essential for understanding larger conceptual structures within a language, and that this in turn aids the analysis of literary texts and understanding of Anglo-Saxon psychologies.

<p>Patients suffering from different forms of neurodegenerative diseases, such as: Creutzfeldt Jacob Disease (CJD), Alzheimer disease (AD), mild cognitive impairment (MCI), frontotemporal dementia and Parkinson’s disease (PD) were examined with Positron Emission Tomography (PET) and the combination of different radiotracers: ¹⁵O-water, N-[¹¹C-methyl]-L-deuterodeprenyl (DED), [¹⁸F] 2-fluorodeoxyglucose: (FDG), N-methyl-[¹¹C]2-(4-methylaminophenyl)-6-hydroxybenzothiazole (PIB) and L-[¹¹C]-3,4-dihydroxiphenyl-alanine (DOPA). The radiotracers and the combinations of different radiotracers were selected with the intention to detect, in the brain, patterns of neuronal dysfunction, astrocytosis, axon degeneration or protein aggregation (amyloid), in the brain which are pathognomonic for specific diseases and may contribute to improve clinical differential diagnoses. Examinations in healthy volunteers were performed to allow comparisons with patients. In addition, animal studies were conducted to complement the information. In some cases, the PET findings could be compared with the results of autopsies.</p><p>In contrast to the micropathology, in which only a limited part of a tissue (obtained post-mortem or by biopsy) is inspected, one PET acquisition provides an image of the whole system (e.g.: the brain and the cerebellum). This form of imaging pathology is “<i>in vivo</i>”, where the examination is innocuous for the patient. </p><p>This thesis is an attempt to stimulate the development of new tracers, new tracer combinations and methods that directly or indirectly describe the anatomo-physiopathological changes produced in the brain in neurodegenerative diseases. A better description of different diseases can be obtained, confirming or questioning the clinical diagnoses and widening our understanding of the mechanisms underlying neurodegeneration. Different pathologies can produce similar symptoms and thus causing confusion regarding clinical diagnosis. The used PET combinations improved the accuracy of the diagnoses. The incipient knowledge emerging from a new neuroimaging pathology in combination with other disciplines may open the way to new classifications of dementias and neurodegenerative diseases based on an “<i>in vivo</i>” pathology. </p>

Antiretroviral drugs have revolutionized HIV care and enabled better management of the infection thus allowing patients survive for many years. One proposed approach to increase access to such drugs in sub-Saharan Africa is to use of a reduced-dose alternative of the drug efavirenz, with 400 mg rather than regular 600 mg dose. This effectively would provide medication for 50 percent more persons with the same amount of active ingredient. However, antiretroviral drugs require high patient adherence to achieve intended therapeutic effect, and it is unclear if a reduced-dose therapy would have sufficient efficacy, and if it would lead to an increased risk of viral resistance. The time profile of drug plasma concentration and corresponding long-term viral load was estimated using integrated population PK/PD simulations, with model parameters based on selected research studies. The results suggest a reduced dose 400 mg, rather than 600 mg regular dose, efavirenz in HIV therapy would place strict demands on patients to maintain very high adherence levels, at least 80-90 percent, to maintain sufficient drug concentration in blood plasma, and to minimize risk of viral failure. However, it is relatively rare for HIV therapy programs in sub-Saharan Africa to consistently achieve such high adherence levels. In addition, if patients are co-administered rifampin, a drug widely used in TB care, this increases hepatic metabolism and plasma clearance rate, resulting in further reduced average drug plasma concentration. These findings suggest a reduced dose efavirenz treatment alternative may be most (only) relevant for patient categories expected to maintain high adherence; and in particular among persons who have been confirmed to have CYP2B6 genotype consistent with inherently lower drug metabolism. At usual adherence levels it is estimated a reduced dose alternative may increase the share of patients at risk of viral failure by 5 to 15 percent vs. regular dose of 600 mg.

The dissertation describes Pd0-catalyzed formal 1,3-diaza-Claisen rearrangement and the design and development of cationic 1,3-diaza-Claisen rearrangement. Our previous work has shown that isocyanates react with azanorbornenes and azabicyclo[2.2.2]octenes under thermal conditions to afford zwitterionic intermediates that undergo a thermal 1,3-diaza-Claisen rearrangement to give both ureas and isoureas. However, some azanorbornenes and azabicyclooctenes failed to rearrange or proceeded in low yields. To address these challenging substrates for the thermal 1,3-diaza-Claisen rearrangement, we have developed a Pd0-catalyzed formal 1,3-diaza-Claisen rearrangement. Interestingly, under Pd0-catalyzed condition, both isocyanates with electron-withdrawing groups and isocyanates without electron-withdrawing groups react with azanorbornenes and azabicyclo[2.2.2]octenes to provide ureas as the only products in high yields. More importantly, the reactions that failed under thermal conditions were all successful under Pd0-catalysis. In addition to azanorbornenes and azabicyclo[2.2.2]octenes, other ring systems were also investigated. Pd0 catalysis has broadened the scope of tertiary allylic amines that react with isocyanates to afford 1,3-diaza-Claisen rearrangement products. In the presence of p-TsCl and NEt3, allylaminopropyl benzyl ureas were initially dehydrated to form protonated carbodiimides whose presence was confirmed by the infrared absorption frequency at 2100 cm-1 which is the characteristic band of -N=C=N-; then the in situ generated protonated carbodiimides were poised for further cationic 1,3-diaza-Claisen rearrangement to afford synthetically challenging guanidines. The effect of acid on the rearrangement was ascertained by the fact that no rearrangement product was observed by simply heating free base carbodiimide 3.10 in benzene at reflux. Other dehydration reagents, such as Tf2O, Ts2O, MsCl were also investigated, and none of them provide satisfactory results. A selection of allyamino benzyl ureas with different tether length, substituents, or in varied ring systems, were synthesized to explore the scope of this methodology. This methodology works best at allylaminopropyl benzyl ureas, and the substituents on the benzyl group does not seem to affect the reaction rate in a significant way.

Un des mécanismes d’évasion des cellules tumorales au système immunitaire fait intervenir la famille des molécules de type B7. Ces molécules de costimulation ont aussi un rôle dans les mécanismes de tolérance immunitaire. La molécule B7-H1 (PD-L1 ou CD274) inhibe directement les lymphocytes T cytotoxiques (CTL) et est fortement exprimée à la surface de nombreux types de cellules tumorales. Les mécanismes de régulation de son expression ne sont pas bien connus. Il existe une augmentation d’expression de cette molécule après stimulation par l’IFN&#947; et récemment les ligands des Toll-Like-Receptor (TLR) 2, 4 et 9 ont été impliqués dans sa régulation au niveau du myélome multiple. L’implication possible des TLR dans l’expression de B7-H1 suggère un rôle possible de pathogènes dans l’échappement des tumeurs au système immunitaireIl n’existe aucune donnée dans la littérature sur l’expression des TLR au niveau des cellules blastiques de patients atteints de leucémies aigues myéloblastique (LAM). Nous avons dans un premier temps étudié l’expression des TLR dans les LAM et l’inductibilité de l’expression de la molécule B7-H1 par les ligands des TLR en cytométrie en flux. Nos résultats montrent que les TLR sont exprimés dans les LAM, avec une grande variabilité suivant les patients. On observe une augmentation significative de l’expression de B7-H1 après stimulation par le LPS (ligand TLR4) alors qu’elle n’est pas significative pour les autres ligands (PGN et ODN). Comme dans les tumeurs solides et le myélome multiple, l’expression de B7-H1 est augmentée par l’IFN &#947;. Des tests de lyse CTL sont en cours afin de confirmer le rôle fonctionnel de cette expression de B7-H1 via les TLR dans les LAM.Une autre partie de l’étude a été réalisée sur deux lignées murines leucémiques : DA1-3B et WEHI-3B, afin de disposer de modèles expérimentaux d’expression de B7-H1. On retrouve sur ces deux modèles l’augmentation d’expression de B7-H1 après stimulation par l’IFN &#947; et les ligands des TLR. L’utilisation de différents inhibiteurs chimiques des voies de signalisation suggère le rôle des voies MEK/ERK et de la voie JAK/STAT dans l’expression de cette molécule. La voie PI3kinase/Akt semble au contraire jouer un rôle inhibiteur. Le travail se poursuit avec la transfection de transdominants négatifs des différentes voies et de mutants constitutivement actifs. L’objectif à terme est de tester des stratégies d’immunothérapies des LAM par blocage pharmacologique de l’expression de B7-H1. / B7-H1 (PD-L1) is a B7-related protein that inhibits T-cell responses. B7-H1 participates in the immunoescape of cancer cells and is also involved in the long-term persistence of leukemic cells in a mouse model. B7-H1 can be constitutively expressed by cancer cells but is also induced by various stimuli. We therefore examined the constitutive and inducible expression of B7-H1 and the consequences of expression in human acute myeloid leukemia (AML). We analyzed B7-H1 expression in a cohort of 79 patients with AML. Blast cells were also studied after incubation with interferon-gamma or TLR ligands. Functionality was evaluated by cytotoxic T-cell activity against blast cells. Expression of B7-H1 at diagnosis was high in 18% of patients. Expression of toll-like receptors (TLR) 2, 4, and 9 was detected in one-third of AML samples. Expression of TLR2 and TLR4 ligands or IFN-&#61543; induced by B7-H1 was found to protect AML cells from CTL-mediated lysis. Spontaneous B7-H1 expression was also found to be enhanced at relapse in some patients. MEK inhibitors including UO126 and AZD6244 reduced B7-H1 expression and restored CTL-mediated lysis of blast cells. In AML, B7-H1 expression by blasts represents a possible immune escape mechanism. The inducibility of B7-H1 expression by IFN-&#61543; or TLR ligands suggests that various stimuli, either produced during the immune response against leukemia cells or released by infectious microorganisms, could protect leukemic cells from T-cells. The efficacy of MEK inhibitors against B7-H1-mediated inhibition of CTLs suggests a possible cancer immunotherapy strategy using targeted drugs.

The widespread application of pressurized SF6 gas and its mixtures as insulating medium in many electric power applications is the result of recent advances in technologies. The likelihood of failure for a Gas Insulated Substation or Transmission Line (GIS/GITL) is primarily due to the presence of defects inside the equipment. Defects can be introduced into the GIS/GITL system for various reasons. Partial discharge (PD) is a natural phenomenon occurring in the GIS/GITL systems, which invariably contains defects. During commissioning or routine tests PD measurements serve to identify the type and status of a defect. Of particular interest for this research work will be the critical review of PD measurement for different types of free conducting particles in the gas using the UHF method due to its superiority among others. The work highlights the integrity of the method as a tool for both commissioning and routine tests and its alignment with the high voltage SF6 test standards is reviewed. 80/20 N2/SF6 mixture is used to reduce the surface roughness effect in pure SF6, as well as for the reduction of economical and environmental risks.

Introdução: apesar de depressão e dor serem altamente prevalentes em pacientes com Doença de Parkinson (DP), há poucos estudos sobre a relação entre esses fatores, apesar da já bem descrita potencial modulação da dor por estados emocionais. Objetivo: avaliar a percepção termoalgésica de calor e dor em método quantitativo e correlacioná-la com sintomas psiquiátricos e da Doença de Parkinson. Método: realizamos um estudo transversal avaliando características clínicas e dados psicofísicos em 31 pacientes com DP sob efeito da medicação dopaminérgica (estado “on”). Verificamos as características da DP utilizando a escala Hoehn and Yahr, realizamos uma avaliação psiquiátrica usando as escalas Inventário de Depressão de Beck (Inventário de Depressão de Beck - IDB), Mini International Neuropsychiatric Interview (MINI) de acordo com os critérios do DSM IV, e Mini Mental State Evaluation (MMSE), avaliamos queixas de dor nos últimos 90 dias usando uma escala visual analógica para dor (EVA – Escala Visual Analógica) e medimos a percepção termoalgésica através do Teste Quantitativo Sensitivo (TQS) para percepção de calor e de dor. Resultados: 31 pacientes foram avaliados. Surpreendentemente, não houve associação entre a percepção termoalgésica e as queixas de dor ou sintomas da DP. Entretanto, houve uma correlação moderada mas significativa entre sintomas depressivos medidos pela BDI e os limiares de calor e de dor (r=0.54 para calor p<0.05 e r=0.47 p<0.05 para dor). Pacientes com sintomas depressivos significativos tiveram limiares de calor e de dor maiores comparados aos sem sintomas depressivos. Esse achado se manteve após correção estatística para severidade dos sintomas da DP. Conclusão: processamento termoalgésico em pacientes com DP é mais influenciado por depressão do que pela severidade da Doença de Parkinson ou pelo nível da dor em si. Essa informação tem implicações importantes para o diagnóstico e abordagem terapêutica para pacientes com DP e dor e/ou depressão. Por exemplo, a depressão poderia ser mais sistematicamente rastreada e tratada em pacientes com DP com processamento de dor alterado. / Introduction: Although depression and pain are highly prevalent in Parkinson’s Disease (PD) patients, there is a lack of studies in their relationship, even though it is well-known that pain is potentially modulated by emotional state. Aims: To assess warm and heat pain perception in a quantitative method and correlate it with psychiatric and parkinsonian symptoms. Methods: We carried out a transversal study assessing clinical and psychophysical data in 31 patients with PD during the effect of dopaminergic medication (on state). We assessed the clinical characteristics of Parkinson's using Hoehn and Yahr (HY), performed a psychiatric evaluation using Beck Depression Inventory (BDI), Mini International Neuropsychiatric Interview (MINI) according to the DSM IV criteria and Mini Mental State Evaluation (MMSE), evaluated pain complaints in the last 90 days using a visual analogue scale for pain (VAS) and measured pain perception by means of quantitative sensory testing (QST) for warm and heat pain perception. Results: 31 patients were evaluated. Surprisingly, there was no association between thermoalgesic perception with pain complaints or parkinsonian symptoms. However, there was a moderate but significant correlation between depressive symptoms measured by BDI and warm sensation and heat pain thresholds(r=0.54 for warm p<0.05 and r=0.47 p<0.05 for heat pain). Patients with significant depressive symptoms had higher warm and heat pain thresholds compared to those without depression. This finding was maintained after statistical correction for the PD symptoms severity. Conclusion: Thermoalgesic processing in PD patients is more influenced by depression than by PD severity or level of pain itself. This information has important implications for diagnostic and therapeutic approaches for patients with PD and pain and/or depression. For instance, depression might be more systematically screened and treated in PD patients with altered pain processing.

INTRODUCTION: Melanoma is the most deadly skin cancer with mortality dependent on the extent and location of metastases. Lymphatic metastasis occurs early in melanoma, and tumor-associated lymphatic vessel area correlates with melanoma progression. Recently, the discovery of checkpoint inhibitors has drastically changed the treatment strategy and survival rates in melanoma. Neuropilin-2 (NRP2) is a potential common target in melanoma cells, tumor-associated lymphatic endothelial cells (LECs) and tumor-infiltrating lymphocytes (TILs). NRP2 is a cell surface receptor with competing stimulatory ligands (VEGF-A/-C) and inhibitory ligands (SEMA3F/G). AIM: The goal of this study was to investigate the role of NRP2 in both melanoma cells and the melanoma microenvironment (LECs, TILs) and to examine the effect of semaphorin 3F (SEMA3F) on the tumor cells as well as an immune modulator. RESULTS: Mouse and human melanocytes expressed NRP2 but not other vascular endothelial growth factor (VEGF) receptor tyrosine kinases in vitro and in vivo. NRP2 protein expression, as analyzed by immunohistochemistry, was upregulated in human metastatic melanoma sections. Treatment of melanoma cells in vitro with SEMA3F inhibited migration and phosphorylation of protein kinase B (AKT) but did not inhibit cell viability. SEMA3F also increased programmed cell death-ligand 1 (PD-L1) expression in melanoma. Syngeneic B16F10 melanoma did not grow in global NRP2 knockout (KO) mice but did grow in wild-type mice. In addition, mice inoculated with B16F10 were treated with SEMA3F or phosphate-buffered saline (PBS) by mini-osmotic pumps. Resulting tumors were analyzed histologically for microvessel density and presence of TILs (number and subtype). CONCLUSIONS: Expression of NRP2 protein positively correlated with melanoma progression in human patient samples. NRP2 functions differently in melanoma tumor cells than in host stromal cells (endothelial cells [ECs], LECs). In melanoma, NRP2 is not a VEGF receptor but responds to the ligand, SEMA3F. Alternately, NRP2 appears to be an important VEGF-A/-C co-receptor in tumor-associated angiogenesis and lymphangiogenesis, as demonstrated in the NRP2 transgenic mice studies. SEMA3F inhibited tumor cell migration but increased PD-L1 expression. Systemic treatment with purified SEMA3F protein in melanoma preclinical trials inhibited melanoma growth and microvessel density. Taken together, these results suggest that exploiting the NRP2/SEMA3F signaling axis may be a novel treatment strategy to be used in combination with existing immunotherapy in melanoma. / 2020-07-03T00:00:00Z

Tese de Mestrado Integrado. Engenharia Electrotécnica e de Computadores. Faculdade de Engenharia. Universidade do Porto. 2012